Loading...
•
Jan 31, 2022
Cooper Q1 2022 Earnings Report
Cooper reported a strong start to fiscal 2022 with revenue increasing 16% year-over-year.
Key Takeaways
CooperCompanies announced strong first quarter results with revenue up 16% year-over-year to $787.2 million. CooperVision revenue increased by 11% and CooperSurgical revenue increased by 30%. GAAP diluted earnings per share were $1.91, while non-GAAP diluted earnings per share were $3.24, a 2% increase from the previous year.
Revenue increased 16% year-over-year to $787.2 million.
CooperVision revenue was up 11% to $561.5 million.
CooperSurgical revenue was up 30% to $225.7 million.
Non-GAAP diluted earnings per share were $3.24, up 2% from last year's first quarter.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Office & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
Fiscal Year 2022 total revenue is expected to be $3,261 - $3,329 million with organic growth of 6.5% to 8.5%. CVI revenue is expected to be $2,221 - $2,264 million with organic growth of 7% to 9%. CSI revenue is expected to be $1,040 - $1,065 million with organic growth of 5% to 7%. Fiscal 2022 non-GAAP diluted EPS is expected to be $13.70 - $14.20.
Positive Outlook
- Fiscal 2022 total revenue $3,261 - $3,329 million (organic growth of 6.5% to 8.5%)
- CVI revenue $2,221 - $2,264 million (organic growth of 7% to 9%)
- CSI revenue $1,040 - $1,065 million (organic growth of 5% to 7%)
- Fiscal 2022 non-GAAP diluted EPS $13.70 - $14.20
Challenges Ahead
- The continuing COVID-19 pandemic presents ongoing global risks to our markets and businesses.
- The recent outbreak of war in Ukraine present ongoing global risks to our markets and businesses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income